{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:29:48Z","timestamp":1782761388826,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals North America Inc.","doi-asserted-by":"publisher","award":["08-021LUB"],"award-info":[{"award-number":["08-021LUB"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals North America Inc.","doi-asserted-by":"publisher","award":["NIH 2R01-DK091281"],"award-info":[{"award-number":["NIH 2R01-DK091281"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals North America Inc.","doi-asserted-by":"publisher","award":["1R01AI153314"],"award-info":[{"award-number":["1R01AI153314"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceuticals North America Inc.","doi-asserted-by":"publisher","award":["R21AI152017"],"award-info":[{"award-number":["R21AI152017"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"Crohn\u2019s and Colitis Foundation Senior Research Award","doi-asserted-by":"publisher","award":["08-021LUB"],"award-info":[{"award-number":["08-021LUB"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"Crohn\u2019s and Colitis Foundation Senior Research Award","doi-asserted-by":"publisher","award":["NIH 2R01-DK091281"],"award-info":[{"award-number":["NIH 2R01-DK091281"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"Crohn\u2019s and Colitis Foundation Senior Research Award","doi-asserted-by":"publisher","award":["1R01AI153314"],"award-info":[{"award-number":["1R01AI153314"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"Crohn\u2019s and Colitis Foundation Senior Research Award","doi-asserted-by":"publisher","award":["R21AI152017"],"award-info":[{"award-number":["R21AI152017"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The prostone analog, lubiprostone, is approved to manage constipation-predominant irritable bowel syndrome. Lubiprostone also protects intestinal mucosal barrier function in animal models of colitis. The aim of this study was to determine if lubiprostone improves barrier properties in isolated colonic biopsies from Crohn\u2019s disease (CD) and ulcerative colitis (UC) patients. Sigmoid colon biopsies from healthy subjects, CD and UC patients in remission, and CD patients with active disease were mounted in Ussing chambers. Tissues were treated with lubiprostone or vehicle to determine the effects on transepithelial electrical resistance (TER), FITC-dextran 4kD (FD4) permeability, and electrogenic ion transport responses to forskolin and carbachol. Localization of the tight junction protein, occludin, was determined by immunofluorescence. Lubiprostone significantly increased ion transport across control, CD and UC remission biopsies but not active CD. Lubiprostone selectively improved TER in both CD remission and active disease biopsies but not in control or UC biopsies. The improved TER was associated with increased membrane localization of occludin. Lubiprostone selectively improved barrier properties of biopsies from CD patients vs. UC and independent of an ion transport response. These data indicate that lubiprostone has potential efficacy in improving mucosal integrity in Crohn\u2019s disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics15030811","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T03:54:56Z","timestamp":1677729296000},"page":"811","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn\u2019s Disease but Not Ulcerative Colitis Patients"],"prefix":"10.3390","volume":"15","author":[{"given":"Young Su","family":"Park","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"Department of Internal Medicine, Division of Gastroenterology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1946-7896","authenticated-orcid":false,"given":"Sang Bum","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"Division of Gastroenterology, Department of Internal Medicine, St. Mary\u2019s Hospital, Catholic University of Korea, Seoul 06591, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald R.","family":"Marchelletta","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison M.","family":"Penrose","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos","family":"Ruiter-Visser","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"Department of Internal Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Docherty","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid S.","family":"Boland","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6286-0802","authenticated-orcid":false,"given":"Declan F.","family":"McCole","sequence":"additional","affiliation":[{"name":"Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 307 SOM Research Building, 900 University Ave, Riverside, CA 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s10620-011-1702-2","article-title":"Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome","volume":"56","author":"Schey","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/17425255.4.8.1091","article-title":"Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders","volume":"4","author":"Ginzburg","year":"2008","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"C1173","DOI":"10.1152\/ajpcell.00528.2003","article-title":"SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents","volume":"287","author":"Cuppoletti","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"C479","DOI":"10.1152\/ajpcell.00077.2014","article-title":"Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents","volume":"307","author":"Cuppoletti","year":"2014","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"C707","DOI":"10.1152\/ajpcell.00267.2016","article-title":"Identification of the fatty acid activation site on human ClC-2","volume":"312","author":"Cuppoletti","year":"2017","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"G234","DOI":"10.1152\/ajpgi.00366.2007","article-title":"A synthetic prostone activates apical chloride channels in A6 epithelial cells","volume":"295","author":"Bao","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"G823","DOI":"10.1152\/ajpgi.90447.2008","article-title":"Stimulation of mucosal secretion by lubiprostone (SPI-0211) in guinea pig small intestine and colon","volume":"296","author":"Fei","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2009.05.037","article-title":"Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator","volume":"137","author":"Bijvelds","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10620-010-1495-8","article-title":"Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84","volume":"56","author":"Ao","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10620-009-0907-0","article-title":"Lubiprostone stimulates duodenal bicarbonate secretion in rats","volume":"54","author":"Mizumori","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.bbrc.2012.08.097","article-title":"Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4))","volume":"426","author":"Norimatsu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"L324","DOI":"10.1152\/ajplung.00277.2012","article-title":"Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia","volume":"304","author":"Schiffhauer","year":"2013","journal-title":"Am. J. Physiol. Lung. Cell Mol. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s10620-012-2352-8","article-title":"Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility","volume":"57","author":"Jakab","year":"2012","journal-title":"Dig. Dis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arakawa, K., Ishigami, T., Nakai-Sugiyama, M., Chen, L., Doi, H., Kino, T., Minegishi, S., Saigoh-Teranaka, S., Sasaki-Nakashima, R., and Hibi, K. (2019). Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218096"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G647","DOI":"10.1152\/ajpgi.00183.2006","article-title":"Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone","volume":"292","author":"Moeser","year":"2007","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3164\/jcbn.10-79","article-title":"The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine","volume":"48","author":"Matsui","year":"2011","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/jpet.114.213991","article-title":"Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors","volume":"349","author":"Hayashi","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e1105906","DOI":"10.1080\/21688370.2015.1105906","article-title":"ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target","volume":"3","author":"Jin","year":"2015","journal-title":"Tissue Barriers"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kato, T., Honda, Y., Kurita, Y., Iwasaki, A., Sato, T., Kessoku, T., Uchiyama, S., Ogawa, Y., Ohkubo, H., and Higurashi, T. (2017). Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175626"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"C1787","DOI":"10.1152\/ajpcell.2000.279.6.C1787","article-title":"Expression of the chloride channel ClC-2 in the murine small intestine epithelium","volume":"279","author":"Gyomorey","year":"2000","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1053\/j.gastro.2004.06.004","article-title":"ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum","volume":"127","author":"Moeser","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.3748\/wjg.14.6012","article-title":"Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine","volume":"14","author":"Moeser","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"C178","DOI":"10.1152\/ajpcell.00072.2011","article-title":"Chloride channel ClC-2 modulates tight junction barrier function via intracellular trafficking of occludin","volume":"302","author":"Nighot","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yexcr.2017.01.024","article-title":"Chloride channel ClC- 2 enhances intestinal epithelial tight junction barrier function via regulation of caveolin-1 and caveolar trafficking of occludin","volume":"352","author":"Nighot","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yexcr.2008.10.001","article-title":"ClC-2 is required for rapid restoration of epithelial tight junctions in ischemic-injured murine jejunum","volume":"315","author":"Nighot","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"G449","DOI":"10.1152\/ajpgi.00520.2009","article-title":"ClC-2 regulates mucosal barrier function associated with structural changes to the villus and epithelial tight junction","volume":"299","author":"Nighot","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1097\/MIB.0b013e3182a82ae9","article-title":"Chloride channel ClC-2 is a key factor in the development of DSS-induced murine colitis","volume":"19","author":"Nighot","year":"2013","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1097\/MIB.0000000000000090","article-title":"IBD candidate genes and intestinal barrier regulation","volume":"20","author":"McCole","year":"2014","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1749-6632.2012.06612.x","article-title":"Abnormal intestinal permeability in Crohn\u2019s disease pathogenesis","volume":"1258","author":"Teshima","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/0140-6736(93)90882-H","article-title":"Intestinal permeability and the prediction of relapse in Crohn\u2019s disease","volume":"341","author":"Wyatt","year":"1993","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7326\/0003-4819-105-6-883","article-title":"Increased intestinal permeability in patients with Crohn\u2019s disease and their relatives. A possible etiologic factor","volume":"105","author":"Hollander","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"ref_34","first-page":"537","article-title":"A freeze fracture study of Crohn\u2019s disease of the terminal ileum: Changes in epithelial tight junction organization","volume":"78","author":"Marin","year":"1983","journal-title":"Am. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12037","DOI":"10.1074\/jbc.M109.064808","article-title":"Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity","volume":"285","author":"Weber","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.2006.094375","article-title":"Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn\u2019s disease","volume":"56","author":"Zeissig","year":"2007","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Marchelletta, R.R., Krishnan, M., Spalinger, M.R., Placone, T.W., Alvarez, R., Sayoc-Becerra, A., Canale, V., Shawki, A., Park, Y.S., and Bernts, L.H. (2021). T cell protein tyrosine phosphatase protects intestinal barrier function by restricting epithelial tight junction remodeling. J. Clin. Investig., 131.","DOI":"10.1172\/JCI138230"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000503054","article-title":"Lubiprostone Induces Claudin-1 and Protects Intestinal Barrier Function","volume":"105","author":"Nishii","year":"2020","journal-title":"Pharmacology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e13477","DOI":"10.1111\/nmo.13477","article-title":"Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human","volume":"31","author":"Zong","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1097\/MIB.0000000000000550","article-title":"Pharmaceutical Activation or Genetic Absence of ClC-2 Alters Tight Junctions During Experimental Colitis","volume":"21","author":"Jin","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.1002\/prp2.128","article-title":"A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa","volume":"3","author":"Kang","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/ecco-jcc\/jjab085","article-title":"Immunological Networks Defining the Heterogeneity of Inflammatory Bowel Diseases","volume":"15","author":"Selin","year":"2021","journal-title":"J. Crohns. Colitis."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"De Lisle, R.C. (2012). Lubiprostone stimulates small intestinal mucin release. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-156"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s10620-012-2509-5","article-title":"Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota","volume":"58","author":"Musch","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1748-1716.1988.tb08462.x","article-title":"The importance of the subepithelial resistance for the electrical properties of the rat jejunum in vitro","volume":"134","author":"Hemlin","year":"1988","journal-title":"Acta. Physiol. Scand."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"G1151","DOI":"10.1152\/ajpgi.90649.2008","article-title":"A guide to Ussing chamber studies of mouse intestine","volume":"296","author":"Clarke","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.gastro.2005.06.004","article-title":"Epidermal growth factor partially restores colonic ion transport responses in mouse models of chronic colitis","volume":"129","author":"McCole","year":"2005","journal-title":"Gastroenterology"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/811\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:45:51Z","timestamp":1760121951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/3\/811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["pharmaceutics15030811"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15030811","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]}}}